Metropolitan Life Insurance CO Olema Pharmaceuticals, Inc. Transaction History

Metropolitan Life Insurance CO

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	BUY	$3.22 - $9.65 $4,974 - $14,909	1,545 New	1,545 $13,000
Q1 2022 May 12, 2022	SELL	$3.89 - $9.43 $28,175 - $68,301	-7,243 Closed	0 $0
Q4 2021 Jun 21, 2023	BUY	$8.75 - $30.71 $63,376 - $222,432	7,243 New	7,243 $67,000
Q3 2021 Jun 21, 2023	BUY	$22.96 - $30.13 $166,299 - $218,231	7,243 New	7,243 $199,000
Q3 2021 Mar 30, 2023	BUY	$22.96 - $30.13 $60,361 - $79,211	2,629 Added 56.98%	7,243 $199,000
Q3 2021 Nov 15, 2021	BUY	$22.96 - $30.13 $60,361 - $79,211	2,629 Added 56.98%	7,243 $200,000
Q2 2021 Jun 21, 2023	BUY	$21.15 - $36.14 $97,586 - $166,749	4,614 New	4,614 $129,000
Q2 2021 Mar 30, 2023	BUY	$21.15 - $36.14 $10,849 - $18,539	513 Added 12.51%	4,614 $129,000
Q2 2021 Aug 16, 2021	BUY	$21.15 - $36.14 $97,501 - $166,605	4,610 Added 115250.0%	4,614 $129,000
Q1 2021 Jun 26, 2023	BUY	$27.81 - $53.64 $114,048 - $219,977	4,101 New	4,101 $136 Million
Q1 2021 Mar 30, 2023	BUY	$27.81 - $53.64 $114,048 - $219,977	4,101 New	4,101 $136,000
Q1 2021 May 14, 2021	BUY	$27.81 - $53.64 $111 - $214	4 New	4 $136,000

145

58.3M

141K

23.1K

Ticker OLMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,419,600
Market Cap $248M
Description
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.